MIV Therapeutics Claims of Total Biocompatibility of Hydroxyapatite Confirmed by Independent Scientific Studies
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Investors:
Dan Savino,...
MIV Therapeutics Expands Intellectual Property for Multi-layer/Multi-drug Delivery Systems with Two New Patent Applications
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Dan Savino,...
t Pulse Announces its Hot Stock Alerts for Thursday, March 31, 2005: SWKD, AAPL, MIVT, QCOM
ATLANTA, March 31, 2005 (PRIMEZONE) -- Market Pulse is pleased to introduce our featured stock, Small...
Technologies Program with Appointment Of Dr. Dean-Mo Lui as Chief Scientist
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Investors:
Dan Savino, 800-221-5108 ext.16
fax: 604-301-9546
...
MIV Therapeutics Builds Strength of Drug-Delivery Technologies Program with Appointment of Dr. Dean-Mo Lui as Chief Scientist
Industry-Renowned Scientist Brings Extensive Leadership in Development...
#8: MIVT Fourteen Under-Recognized Companies Present New Opportunities This Saturday at the SCIA National Small Cap Southern California Investment Conference in Orange County
Fourteen Under-Recognized Companies Present New Opportunities This Saturday at the SCIA National Small Cap Southern California Investment Conference in Orange County
MONARCH BEACH, CA - MARKET...
Expect the Best This Saturday at the SCIA National Small Cap Conference Offered to the Financial Community April 2nd in Orange County
MONARCH BEACH, CA - MARKET WIRE - 03/29/05
Southern...
#6: MIVT Web Alert: Biophan Technologies, MIV Therapeutics and Xenomics to Present at Trilogy Capital's Biotechnology Forum Today at 12:00 Noon -ET-; Online Conference Provides Overviews of Products and Growth Strategies
Web Alert: Biophan Technologies, MIV Therapeutics and Xenomics to Present at Trilogy Capital's Biotechnology Forum Today at 12:00 Noon -ET-; Online Conference Provides Overviews of Products and...
#4: MIVT MIV Therapeutics CEO Discusses Company's Advanced Stent Technology in Online Interview with SmallcapInsights.com; CEO Alan Lindsay Details New Acquisition Agreements, Nano-coatings and Results of Clinical Trials
MIV Therapeutics CEO Discusses Company's Advanced Stent Technology in Online Interview with SmallcapInsights.com; CEO Alan Lindsay Details New Acquisition Agreements, Nano-coatings and Results of...
#3: MIVT MIV Therapeutics Announces 2004 Year-End Review: Milestones Achieved in Development of Revolutionary Coatings for Medical Devices; Technology Increases Body's Acceptance of Implanted Devices, Provides Advanced Therapeutic Functionality
MIV Therapeutics Announces 2004 Year-End Review: Milestones Achieved in Development of Revolutionary Coatings for Medical Devices; Technology Increases Body's Acceptance of Implanted Devices,...
#2: MIVT MIV Therapeutics and Sahajanand Medical Technologies to Join Forces to Form World Class Drug-Eluting Coronary Stent Company Transaction will Bring Company $20 Million Approximate Annual Revenues and International Production and Distribution
MIV Therapeutics and Sahajanand Medical Technologies to Join Forces to Form World Class Drug-Eluting Coronary Stent Company Transaction will Bring Company $20 Million Approximate Annual Revenues...
SISM Research Analyst Reinforces Speculative Buy/4 Rating for MIV Therapeutics Inc.
VANCOUVER - PRNewswire-FirstCall - Feb. 15
VANCOUVER, Feb. 15 /PRNewswire-FirstCall/ -- In a Research Report...